www.fdanews.com/articles/157329-astrazeneca-and-bristol-myers-squibb-resubmit-dapagliflozin-new-drug-application-for-the-treatment-of-type-2-diabetes-in-the-u-s
AstraZeneca and Bristol-Myers Squibb Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S
July 25, 2013
AstraZeneca and Bristol-Myers Squibb have resubmitted a New Drug Application for dapagliflozin for type 2 diabetes. The new submission includes new studies and more long-term data.
AstraZeneca
AstraZeneca